The CD2 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting the CD2 gene in the HeLa background. This product consists of a heterogeneous pool of cells with disrupted CD2 loci, providing a loss-of-function model without single-cell cloning. The polyclonal format reduces clonal artifacts and is suitable for reproducible gene knockout studies. Researchers can employ these cells to interrogate CD2-mediated adhesion and costimulatory signaling in a well-controlled manner.
HeLa is an immortalized human cervical epithelial cell line derived from Henrietta Lacks’ adenocarcinoma tissue. It is a cornerstone of biomedical research due to its robust growth and ease of transfection, enabling efficient genetic manipulation. HeLa has been widely used in cancer biology, virology, and signal transduction, providing a versatile platform for dissecting gene function. Although not of T-cell origin, HeLa offers a tractable system for CD2 functional studies via gene knockout and, if desired, reconstitution.
CD2 is a transmembrane receptor on T cells and NK cells that mediates adhesion and costimulation through binding CD58 on antigen-presenting cells. This interaction amplifies TCR signaling by activating Src kinases Lck and Fyn, leading to PLC??1 phosphorylation and calcium flux. Downstream, CD2 engagement triggers PI3K-Akt and MAPK/ERK pathways, promoting NFAT-driven transcription of cytokines such as IL-2. CD2 also interacts with adaptor CD2BP1 and CD3 complex components, integrating signals essential for immunological synapse formation and full T-cell activation.
In the HeLa backdrop, CD2 knockout establishes a simplified cellular model free of endogenous T-cell signaling, enabling focused analysis of CD2 molecular interactions. The knockout facilitates reconstitution experiments, structure-function studies, and downstream signaling dissection when paired with ectopic expression of CD58 or pathway components. The polyclonal population ensures robustness by averaging out clone-specific variability, making it a reliable tool for repeatable biochemical and imaging-based assays within a well-characterized cancer cell context.
These cells are suited for adhesion assays measuring CD2-CD58 binding, phospho-signaling profiling by western blot or flow cytometry, and NFAT reporter assays to monitor costimulatory activity. Applications include high-throughput immunomodulator screening, autoimmune disease target validation (e.g., rheumatoid arthritis, multiple sclerosis), and investigation of T-cell lymphoma or graft-versus-host disease mechanisms. For further details, please contact Ascent Research.
